| Not Yet Recruiting | Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver Disease NCT07180745 | Badr University | Phase 4 |
| Active Not Recruiting | Efficacy and Tolerability of a Specialized Food Products for Dietary Therapeutic and Preventive Nutrition Base NCT06724913 | Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, Biotechnology | N/A |
| Completed | A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Pre NCT06309992 | Boehringer Ingelheim | Phase 3 |
| Completed | To Evaluate the Efficacy and Safety of HSK31679 in Chinese Patients With Non-Alcoholic Steatohepatitis (NASH) NCT06168383 | Haisco Pharmaceutical Group Co., Ltd. | Phase 2 |
| Active Not Recruiting | Simultaneous Quantification of Liver Fat Content, Fatty Acid Composition, and Fibrosis Using Spin-lock MRI for NCT05384652 | Chinese University of Hong Kong | — |
| Completed | IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) NCT05989711 | Altimmune, Inc. | Phase 2 |
| Completed | A Research Study Looking Into Blood and Urine Levels of the Medicine NNC0194-0499 in the Body and How Well it NCT05727644 | Novo Nordisk A/S | Phase 1 |
| Completed | Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant NCT05712265 | Corcept Therapeutics | Phase 1 |
| Completed | FTIH of ECC4703 in Healthy Volunteers NCT05552274 | Eccogene | EARLY_Phase 1 |
| Completed | Evaluating the Efficacy and Safety of Roflumilast in Patients with NASH NCT06677788 | Tanta University | Phase 2 |
| Completed | Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant NCT05553470 | Corcept Therapeutics | Phase 1 |
| Terminated | Genetic Data Collection in Adult Participants to Identify Genetic Variants of Known Importance in Non-alcoholi NCT05423327 | Regeneron Pharmaceuticals | N/A |
| Unknown | Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis NCT04880187 | Axcella Health, Inc | Phase 2 |
| Active Not Recruiting | A Physiologic Analysis of Endoscopic Sleeve Gastroplasty (ESG) NCT04820036 | Brigham and Women's Hospital | N/A |
| Completed | A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NA NCT04771273 | Boehringer Ingelheim | Phase 2 |
| Active Not Recruiting | Combined Active Treatment in Type 2 Diabetes with NASH NCT04639414 | German Diabetes Center | Phase 4 |
| Withdrawn | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1 NCT04607655 | Galecto Biotech AB | Phase 1 / Phase 2 |
| Completed | A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients NCT04483947 | AstraZeneca | Phase 1 |
| Unknown | The Sonic Incytes Liver Incytes System, Evaluation of Liver Fibrosis and Steatosis Versus MRE and MRI PDFF NCT04682600 | Sonic Incytes | N/A |
| Unknown | A Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of HPN-01 in Healthy Su NCT04481594 | Hepanova Inc. | Phase 1 |
| Completed | Tolerability, Efficacy, and PK of ZSP1601 in Patients With Non-Alcoholic Steatohepatitis (NASH) NCT04140123 | Guangdong Raynovent Biotech Co., Ltd | Phase 1 / Phase 2 |
| Unknown | Efficacy and Safety of Endoscopic Sleeve Gastroplasty Versus Laparoscopic Sleeve Gastrectomy in Obese Subjects NCT04060368 | Instituto de Investigación Marqués de Valdecilla | N/A |
| Unknown | Endoscopic Bariatric Therapy in NASH Cirrhosis NCT04281303 | Instituto de Investigación Marqués de Valdecilla | — |
| Terminated | Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compa NCT04065841 | Novartis Pharmaceuticals | Phase 2 |
| Withdrawn | Natural History of Non Alcoholic Fatty Liver Disease and Predictors of Advanced Fibrosis NCT05050721 | Methodist Health System | — |
| Completed | A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH. NCT04019561 | MedImmune LLC | Phase 2 |
| Completed | A Phase 2b Study of Icosabutate in Fatty Liver Disease NCT04052516 | NorthSea Therapeutics B.V. | Phase 2 |
| Completed | A Pilot Study to Assess the Safety of Oral Insulin in Patients With Nonalcolholic Steatohepatitis (NASH) NCT02653300 | Oramed, Ltd. | Phase 2 |
| Completed | Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients Wit NCT03517540 | Novartis Pharmaceuticals | Phase 2 |
| Completed | A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease NCT02927314 | Can-Fite BioPharma | Phase 2 |
| Recruiting | Longitudinal Observational Study Of Chinese With NAFLD/NASH NCT03151473 | Humanity and Health Research Centre | — |
| Completed | Phase 2b Study in NASH to Assess IVA337 NCT03008070 | Inventiva Pharma | Phase 2 |
| Terminated | Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH NCT02913105 | Novartis Pharmaceuticals | Phase 2 |
| Terminated | Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH) NCT02855164 | Novartis Pharmaceuticals | Phase 2 |
| Active Not Recruiting | Non-alcoholic Fatty Liver Disease Parametric PET (FLiPP) Study NCT02754037 | University of California, Davis | — |
| Completed | A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects NCT02612662 | AstraZeneca | Phase 1 |
| Terminated | Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease ( NCT02605616 | University of Alabama at Birmingham | Phase 2 |
| Terminated | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment NCT02548351 | Intercept Pharmaceuticals | Phase 3 |
| Completed | Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Non NCT02466516 | Gilead Sciences | Phase 2 |
| Completed | A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis NCT02316717 | Immuron Ltd. | Phase 2 |
| Unknown | Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insul NCT02654665 | Changi General Hospital | Phase 3 |
| Completed | DHA and Vitamin D in Children With Biopsy-proven NAFLD NCT02098317 | Bambino Gesù Hospital and Research Institute | Phase 3 |
| Completed | Gut Microbiota and Modulation of Liver Damage in NAFLD NCT02158351 | University of Roma La Sapienza | — |
| Unknown | Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis NCT01950884 | University of Palermo | Phase 4 |
| Recruiting | Blood Collection Biorepository for Liver Disease Research NCT03025074 | State University of New York at Buffalo | — |
| Completed | Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advance NCT01899859 | Galectin Therapeutics Inc. | Phase 1 |
| Completed | Mediterranean Lifestyle Intervention in Patients With Non-alcoholic Fatty Liver Disease NCT01894438 | Harokopio University | N/A |
| Completed | Treatment of Non-alcoholic Steatohepatitis (NASH) Patients With Vitamin D NCT01571063 | University of Zurich | Phase 2 |
| Completed | Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic St NCT01694849 | Genfit | Phase 2 |
| Completed | Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH NCT00706537 | Pfizer | Phase 1 |
| Completed | Exploratory Study to Assess the Short Term Effect on Liver Enzymes and the Safety of TRO19622 in Patients With NCT00666016 | Hoffmann-La Roche | Phase 2 |